Targeting the RANK/RANKL/OPG signaling pathway: A novel approach in the management of osteoporosis

Current Opinion in Investigational Drugs

Volumn 8, Issue 4, 2007, Pages 299-303

  Hamdy, Neveen A T ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Bone mineral density; Bone resorption marker; Denosumab; Fc OPG; Osteoclastogenesis; RANKL antibody; Skeletal and extraskeletal safety

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CYTOKINE; DENOSUMAB; DRUG ANTIBODY; ESTROGEN; GLUCOCORTICOID; HYBRID PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN FC FRAGMENT OSTEOPROTEGERIN FUSION PROTEIN; MONOCLONAL ANTIBODY; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOCLAST DIFFERENTIATION FACTOR ANTIBODY; OSTEOPROTEGERIN; OSTEOPROTEGERIN ANTIBODY; PLACEBO; PROTEIN ANTIBODY; RECOMBINANT PROTEIN; SELECTIVE ESTROGEN RECEPTOR MODULATOR; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ANTIBODY PRODUCTION; BONE ATROPHY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CORTICOSTEROID INDUCED OSTEOPOROSIS; CYTOKINE PRODUCTION; DISEASE EXACERBATION; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG SAFETY; DRUG TARGETING; ENTERITIS; ESTROGEN THERAPY; FRAGILITY FRACTURE; GENE OVEREXPRESSION; HUMAN; HYPERPARATHYROIDISM; HYPOCALCEMIA; IMMUNOPATHOLOGY; INFECTION; LOW DRUG DOSE; MENOPAUSE; NEOPLASM; NONHUMAN; OSTEOCLAST; OSTEOPOROSIS; PARATHYROID HORMONE BLOOD LEVEL; PATHOGENESIS; POSTMENOPAUSE OSTEOPOROSIS; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; THYROTOXICOSIS;

ANIMALS; ANTIBODIES, MONOCLONAL; CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE III; HUMANS; INJECTIONS, SUBCUTANEOUS; OSTEOPOROSIS; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; SIGNAL TRANSDUCTION;

EID: 34147129003     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (35)

1. Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie MT, Martin TJ: Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev (1999) 20(3):345-357.
2. Manolagas SC: Birth and death of bone cells: Basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev (2000) 21(2):115-137.
3. Duong LT, Rodan GA: Regulation of osteoclast formation and function. Rev Endocr Metab Disord (2001) 2(1):95-104.
4. Teitelbaum SL: Bone resorption by osteoclasts. Science (2000) 289(5484):1504-1508.
5. Khosla S: Minireview: The OPG/RANKL/RANK system. Endocrinology (2001) 142(12):5050-5055.
6. Boyle WJ, Simonet WS, Lacey DL: Osteoclast differentiation and activation. Nature (2003) 423(6937):337-342. •• A clear review article providing insight into the mechanisms of osteoclastogenesis and activation of bone resorption with particular reference to the role of the RANK signaling pathway.
7. Baron R: Arming the osteoclasts. Nat Med (2004) 10(5):458-460.
8. Hofbauer LC, Schoppet M: Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. J Am Med Assoc (2004) 292(4):490-495. •• A comprehensive review of the role of alterations in the RANKL/OPG system in the pathogenesis of a number of diseases affecting the skeleton. This review provides an interesting discussion on the potential therapeutic implications of these findings.
9. Tanaka S, Takahashi N, Udagawa N, Tamura T, Akatsu T, Stanley ER, Kurokawa T, Suda T: Macrophage colony-stimulating factor is indispensable for both proliferation and differentiation of osteoclast progenitors. J Clin Invest (1993) 91(1):257-263.
10. Walsh MC, Kim N, Kadono Y, Rho J, Lee SY, Lorenzo J, Choi Y: Osteoimmunology: Interplay between the immune system and bone metabolism. Annu Rev Immunol (2006) 24:33-63. •• An excellent review highlighting the role of the RANK/RANKL/OPG pathway in the interplay between bone and the immune system.
11. Kong YY, Yoshida H, Sarosi I, Tan HL, Timms E, Capparelli C, Morony S, Oliveira-dos-Santos AJ, Van G, Itie A, Khoo W et al: OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature (1999) 397(6717):315-323.
12. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G et al: Osteoprotegerin: A novel secreted protein involved in the regulation of bone density. Cell (1997) 89(2):309-319.
13. Emery JG, McDonnell P, Burke MB, Deen KC, Lyn S, Silverman C, Dul E, Appelbaum ER, Eichman C, DiPrinzio R, Dodds RA et al: Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem (1998) 273(23):14363-14367.
14. Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Capparelli C, Scully S, Tan HL, Xu W, Lacey DL, Boyle WJ, Simonet WS: Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev (1998) 12(9):1260-1268.
15. Hofbauer LC, Khosla S, Dunstan CR, Lacey DL, Spelsberg TC, Riggs BL: Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells. Endocrinology (1999) 140(9):4367-4370.
16. Eghbali-Fatourechi G, Khosla S, Sanyal A, Boyle WJ, Lacey DL, Riggs BL: Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J Clin Invest (2003) 111(8):1221-1230.
17. Shevde NK, Bendixen AC, Dienger KM, Pike JW: Estrogens suppress RANK ligand-induced osteoclast differentiation via a stromal cell independent mechanism involving c-Jun repression. Proc Natl Acad Sci USA (2000) 97(14):7829-7834.
18. Bord S, Ireland DC, Beavan SR, Compston JE: The effects of estrogen on osteoprotegerin, RANKL, and estrogen receptor expression in human osteoblasts. Bone (2003) 32(2):136-141.
19. Hofbauer LC, Gori F, Riggs BL, Lacey DL, Dunstan CR, Spelsberg TC, Khosla S: Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: Potential paracrine mechanisms of glucocorticoid-induced osteoporosis. Endocrinology (1999) 140(10):4382-4389.
20. Sivagurunathan S, Muir MM, Brennan TC, Seale JP, Mason RSL: Influence of glucocorticoids on human osteoclast generation and activity. J Bone Miner Res (2005) 20(3):390-398.
21. Viereck V, Grundker C, Blaschke S, Niederkleine B, Siggelkow H, Frosch KH, Raddatz D, Emons G, Hofbauer LC: Raloxifene concurrently stimulates osteoprotegerin and inhibits interleukin-6 production by human trabecular osteoblasts. J Clin Endocrinol Metab (2003) 88(9):4206-4213.
22. Weitzmann MN, Pacifici R: Estrogen deficiency and bone loss: An inflammatory tale. J Clin Invest (2006) 116(5):1186-1194.
23. Cranney A, Tugwell P, Wells G, Guyatt G, Osteoporosis Methodology Group and The Osteoporosis Research Advisory Group: Meta-analyses of therapies for postmenopausal osteoporosis. I. Systematic reviews of randomized trials in osteoporosis: Introduction and methodology. Endocr Rev (2002) 23(4):496-507.
24. Cranney A, Wells G, Willan A, Griffith L, Zytaruk N, Robinson V, Black D, Adachi J, Shea B, Tugwell P, Guyatt G et al: Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women. Endocr Rev (2002) 23(4):508-516.
25. Cranney A, Tugwell P, Adachi J, Weaver B, Zytaruk N, Papaioannou A, Robinson V, Shea B, Wells G, Guyatt G, Osteoporosis Methodology Group and The Osteoporosis Research Advisory Group: Meta-analyses of therapies for postmenopausal osteoporosis. III. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis. Endocr Rev (2002) 23(4):517-523.
26. Cranney A, Tugwell P, Zytaruk N, Robinson V, Weaver B, Adachi J, Wells G, Shea B, Guyatt G, Osteoporosis Methodology Group and The Osteoporosis Research Advisory Group: Meta-analyses of therapies for postmenopausal osteoporosis. IV. Meta-analysis of raloxifene for the prevention and treatment of postmenopausal osteoporosis. Endocr Rev (2002) 23(4):524-528.
27. Wells G, Tugwell P, Shea B, Guyatt G, Peterson J, Zytaruk N, Robinson V, Henry D, O'Connell D, Cranney A, Osteoporosis Methodology Group and The Osteoporosis Research Advisory Group: Meta-analyses of therapies for postmenopausal osteoporosis. V. Meta-analysis of the efficacy of hormone replacement therapy in treating and preventing osteoporosis in postmenopausal women. Endocr Rev (2002) 23(4):529-539.
28. Cranney A, Tugwell P, Zytaruk N, Robinson V, Weaver B, Shea B, Wells G, Adachi J, Waldegger L, Guyatt G, Osteoporosis Methodology Group and The Osteoporosis Research Advisory Group: Meta-analyses of therapies for postmenopausal osteoporosis. VI. Meta-analysis of calcitonin for the treatment of postmenopausal osteoporosis. Endocr Rev (2002) 23(4):540-551.
29. Min H, Morony S, Sarosi I, Dunstan CR, Caparelli C, Scully S, Van G, Kaufman S, Kostenuil PJ, Lacey DL, Boyle WJ, Simonet WS: Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. J Exp Med (2000) 192(4):463-474.
30. Bekker PJ, Holloway D, Nakanishi A, Arrighi M, Leese PT, Dunstan CR: The effect of a single dose of osteoprotegerin in postmenopausal women. J Bone Miner Res (2001) 16(2):348-360. •• The only study published on the clinical use of OPG in postmenopausal women. This randomized, double-blind, placebo-controlled, sequential dose escalation study evaluated the effect of a single subcutaneous dose of OPG on bone resorption.
31. Bekker PJ, Holloway D, Rasmussen AS, Murphy R, Martin SW, Leese PT, Holmes GB, Dunstan CR, DePaoli AM: A single-dose placebo-controlled study of AMG 162, fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res (2004) 19(7):1059-1066. •• This paper outlines the antiresorptive properties and reversibility of effects of subcutaneous denosumab (AMG-162) in 49 healthy postmenopausal women in a randomized, double-blind, placebo-controlled, dose escalation study, with a follow-up period of 6 to 9 months.
32. McClung MR, Lewiecki EM, Cohen SB, Bolognese MA, Woodson GC, Moffett AH, Peacock M, Miller PD, Lederman SN, Chestnut CH, Lain D et al: Denosumab in postmenopausal women with low bone mineral density. N Engl J Med (2006) 354(8):821-831. •• This 12-month study addresses the efficacy and safety of different doses of denosumab injected at 3 or 6 month intervals compared with weekly alendronate or placebo in 412 postmenopausal women with low BMD. The primary endpoint was changes in BMD at the lumbar spine.
33. NCT00377819: Phase III study of transitioning from alendronate to denosumab. US National Institutes of Health, Bethesda, MD, USA (2007). http://www.clinicaltrials.gov
34. Whyte MP: The long and the short of bone therapy. N Engl J Med (2006) 354(8):860-863.
35. Martin TJ, Seeman E: New mechanisms and targets in the treatment of bone fragility. Clin Sci (2007) 117(2):77-91.